Brought to you by 
Dyax finds antibodies against AstraZeneca target
22 Jul 2002
Executive Summary
During a collaborative research project, Dyax will use its antibody phage display technology to identify, characterize, and optimize antibodies that bind specifically to an AstraZeneca neurological and metabolic disease target.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dyax finds antibodies against AstraZeneca target
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice